<DOC>
	<DOCNO>NCT02801981</DOCNO>
	<brief_summary>This study first evaluate safety , tolerability , pharmacokinetics pharmacodynamics follow single dose 10 milligram ( mg ) 180 mg GSK2330672 Japanese healthy subject . This double-blind , randomize , placebo-controlled , dose-escalating incomplete block crossover study conduct 16 Japanese healthy subject . Study conduct four period ; subject receive either placebo GSK2330672 ( 10 mg , 30 mg , 90 mg 180 mg base randomization ) treatment period . Each period separate washout period ( least 6 day dose ) . Total duration study subject approximately 5 week first dose follow visit .</brief_summary>
	<brief_title>Dose-escalation Study GSK2330672 Japanese Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Cholestasis</mesh_term>
	<criteria>Japanese male age 20 64 year age inclusive , time signing informed consent Healthy determine investigator medically qualify designee base medical evaluation include medical history , physical examination , laboratory test 12lead ECG . A subject clinical abnormality laboratory parameter ( ) is/are specifically list inclusion exclusion criterion , outside reference range population study may include investigator ( consultation Medical Monitor require ) agree document find unlikely introduce additional risk factor interfere study procedure . Regular bowel movement &gt; =1 per two day . Body weight &gt; = 50 kilogram body mass index ( BMI ) equal 18.5 kilogram / square meter ( kg/m^2 ) less 25.0 kg/m^2 Capable give sign informed consent include compliance requirement restriction list consent form protocol . Alanine transaminase ( ALT ) and/or bilirubin &gt; 1.5x Upper limit normal ( ULN ) ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome ) QT interval correct heart rate accord Fridericia 's formula ( QTcF ) &gt; 450 millisecond ( msec ) Current chronic history inflammatory bowel disease , chronic diarrhea , Crohn 's disease malabsorption syndromes . Current chronic history cholelithiasis , inflammatory gall bladder disease , cholestatic liver injury , cholecystecomy . Fecal occult blood test positive screening . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St. John 's Wort ) within 14 day 5 halflives , whichever longer , prior first dose study medication . History regular alcohol consumption within 6 month study define average weekly intake &gt; 14 drink . One drink equivalent 12 gram ( g ) alcohol : 350 millilitre ( mL ) beer , 150 mL wine 45 mL 80 proof distil spirit . History regular use tobacco nicotinecontaining product within 6 month prior screen . History sensitivity heparin heparininduced thrombocytopenia . History sensitivity study medication , component thereof history drug allergy , opinion investigator Medical Monitor , contraindicate participation A positive prestudy syphilis , Hepatitis B surface antigen , Hepatitis C antibody , Human Immunodeficiency Virus ( HIV ) antigen antibody Human Tcell Lymphotropic Virus1 ( HTLV1 ) antibody result screen A positive prestudy urine drug screen . History donation blood blood product &gt; = 400 mL within 3 month &gt; = 200 mL within 1 month prior screen . The subject participate clinical trial receive investigational product within four month 5 halflives ( whichever longer ) prior dose day current study Exposure four new chemical entity within 12 month prior dose day .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>tolerability</keyword>
	<keyword>healthy volunteer</keyword>
	<keyword>Cholestasis</keyword>
	<keyword>safety</keyword>
</DOC>